Tests Hint China's H7N9 Could Be Resistant To Tamiflu, Relenza Flu Drugs
This article was originally published in PharmAsia News
One of the first of China's cases of the H7N9 avian influenza has demonstrated through gene sequencing a resistance to Roche's Tamiflu (oseltamivir) as well as a reduced sensitivity to GlaxoSmithKline's Relenza (zanamivir).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.